Posted by Michael Wonder on 10 Dec 2022
VBI Vaccines announces Health Canada approval for PreHevbrio for the prevention of hepatitis B in adults
8 December 2022 - VBI Vaccines today announced that Health Canada has approved PreHevbrio [3 antigen hepatitis B vaccine (recombinant)] for active immunisation against infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
It can be expected that hepatitis D will also be prevented by immunisation with PreHevbrio as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
